The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Merck & Co. has entered into an agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), to support the manufacturing and supply of J&J’s COVID-19 vaccine. J&J’s COVID-19...
A roundup of news from China (AstraZeneca, Junshi Biosciences), the UK (Pfizer, GSK, CPI), and the US (Gilead Sciences, Merck & Co., AstraZeneca, AbbVie, Mitokinin).
China
AstraZeneca, Junshi Biosciences in Pact for Cancer Drug in China...
Amgen has agreed to acquire Five Prime Therapeutics, a South San Francisco, California-based clinical-stage biopharmaceutical company developing immuno-oncology and targeted cancer therapies, for approximately $1.9 billion.
Five Prime’s lead...
Biogen has announced plans to build a new gene-therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina.
Through the new facility, Biogen aims to expand its existing operations and combined workforce of...
As part of ongoing divestment program of non-core assets following its $62-billion acquisition of Shire in 2019, Takeda Pharmaceutical has agreed to sell select non-core diabetes products in Japan to Teijin Pharma, a Tokyo-based pharmaceutical...
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from Lilly, AstraZeneca, GSK, Novartis, Roche, Pfizer, CureVac, Novavax, and Moderna.
Manufacturing and supply of COVID-19 vaccines and drugs
US Gov’t Purchases...
Perrigo has agreed to sell its generic prescription pharmaceuticals business to Altaris Capital Partners, an investment firm, for $1.55 billion, which includes $1.5 billion in cash.
Perrigo first announced plans in 2018 to separate its...
Novartis has closed on its $2.2-billion licensing agreement and collaboration with BeiGene, a Beijing-based pharmaceutical company, for tislelizumab, an oncology drug. Earlier this year (January 2021), the companies agreed to a $2.2-billion...
Merck KGaA has entered into a global in-licensing agreement with Debiopharm, a Lausanne, Switzerland-based biopharmaceutical company, for the development and commercialization of xevinapant, a treatment for locally advanced squamous cell carcinoma...
Johnson & Johnson (J&J) has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of J&J, to prevent COVID-19 in...
Pfizer/BioNTech, Moderna, and Johnson & Johnson (J&J) have detail plans to increase supply of their respective COVID-19 vaccines to the US. The companies have also provided updates on variant studies.
Supply update: Pfizer/BioNTech
Pfizer...
The latest on manufacturing and potential treatments for COVID-19 with news from the Biden Administration, Sanofi, GlaxoSmithKline, Novavax, and Regeneron.
Manufacturing and supply of COVID-19 vaccines and drugs
President Joe Biden Issues...
The US Food and Drug Administration (FDA) has issued guidances and revised previously published guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential...
Novo Nordisk has announced plans to invest DKK 500 million ($82 million) to expand table production facilities at its site in Måløv, Denmark.
The facility currently manufactures products for oral diabetes treatment and will be expanded to ensure...
Merck & Co. has agreed to acquire Pandion Therapeutics, a Watertown, Massachusetts-based company developing therapeutics for autoimmune diseases, for an approximate total equity value of $1.85 billion.
Pandion is advancing a pipeline of...
